ReviewCancer cell international2025
Harnessing miR-145 in NSCLC: mechanistic roles, diagnostic-prognostic utility, and therapeutic potential.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical significance of miRNAs and exosomal miRNAs in non-small cell lung cancer: diagnostic, prognostic, and therapeutic perspectives.Journal of human genetics · 2026Review
- Harnessing the LncRNA CCAT2 role in gastric cancer: from molecular insights to clinical implications.Cancer cell international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is responsible for most lung cancer diagnoses and causes elevated worldwide mortality rates, mostly due to late detection and the development of resistance against medicines. This review summarizes evidence regarding miR-145, a downregulated NSCLC microRNA, and emphasizes the multifaceted tumor-suppressor activity of miR-145 involving the repression of oncogenes such as c-Myc, epidermal growth factor receptor (EGFR), and octamer-binding transcription factor 4 (OCT4) to restrict cell growth, stemness, epithelial-to-mesenchymal-transition (EMT), metastasis via Phosphoinositide 3-kinases (PI3Ks)/ activation of protein kinase B (AKT, Mitogen‑activated protein kinase (MAPK), and transforming growth factor beta (TGF-β)/Smad signaling. miR-145 also exhibits potential diagnostic specificity in distinguishing NSCLC cases from controls through serum/plasma testing, with greater sensitivity/specificity in multi-miRNA sets, and prognostic value predicting resistance, survival, and disease advancement. Therapeutically, miR-145 enhances responses to chemotherapies, targeted therapies, radiotherapy, and immunotherapies by counteracting resistance networks. Utilizing novel delivery platforms, such as nanoparticles, exosomes, and chemical modifications, may overcome stability and targeting issues that exist with miRNA therapies. Through the integration of preclinical and clinical information, this review helps identify crucial research gaps, such as incompletely defined regulatory networks and the need for large-scale studies, and calls for the application of advanced techniques to expedite the integration of miR-145-based treatments with personalized NSCLC therapy for improved outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.